OABI · OmniAb Inc
United States · RS rating 98 · As of 2026-11-03
| Price | 5.15 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 70 / 97 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 54 / 70 / 65 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +21.4% |
| Sales growth Q/Q | +274.1% |
| Distance from 52-week high | +2.5% |
| Market cap (USD) | $225.9M |